메뉴 건너뛰기




Volumn 73, Issue 13, 2013, Pages 1503-1515

Afatinib: First global approval

Author keywords

[No Author keywords available]

Indexed keywords

AFATINIB; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; FLUOROURACIL; GEFITINIB; GEMCITABINE; NIMOTUZUMAB; PACLITAXEL; PEMETREXED; PLACEBO; RAPAMYCIN; SIMVASTATIN;

EID: 84884640384     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-013-0111-6     Document Type: Article
Times cited : (246)

References (84)
  • 1
    • 79955853698 scopus 로고    scopus 로고
    • The LUX-Lung clinical trial program of afatinib for non-small-cell lung cancer
    • 21554040 10.1586/era.11.34 1:CAS:528:DC%2BC3MXlvFGju7k%3D
    • Metro G, Crino L. The LUX-Lung clinical trial program of afatinib for non-small-cell lung cancer. Expert Rev Anticancer Ther. 2011;11(5):673-82.
    • (2011) Expert Rev Anticancer Ther , vol.11 , Issue.5 , pp. 673-682
    • Metro, G.1    Crino, L.2
  • 2
    • 81155123620 scopus 로고    scopus 로고
    • Role of genotyping in non-small cell lung cancer treatment: Current status
    • 22085382 10.2165/11597700-000000000-00000 1:CAS:528:DC%2BC38Xit1ShtL4%3D
    • Bonanno L, Favaretto A, Rugge M. Role of genotyping in non-small cell lung cancer treatment: current status. Drugs. 2011;71:2231-46.
    • (2011) Drugs , vol.71 , pp. 2231-2246
    • Bonanno, L.1    Favaretto, A.2    Rugge, M.3
  • 3
    • 84878888082 scopus 로고    scopus 로고
    • First-line management of EGFR-mutated advanced lung adenocarcinoma: Recent developments
    • 23479407 10.1007/s40265-013-0020-8
    • Liao B-C, Lin C-C, Yang JC-H. First-line management of EGFR-mutated advanced lung adenocarcinoma: recent developments. Drugs. 2013;73(4):357-69.
    • (2013) Drugs , vol.73 , Issue.4 , pp. 357-369
    • Liao, B.-C.1    Lin, C.-C.2    Yang, J.-H.3
  • 4
    • 79960110757 scopus 로고    scopus 로고
    • Afatinib (BIBW 2992) development in non-small-cell lung cancer
    • 21732753 10.2217/fon.11.62 1:CAS:528:DC%2BC3MXos1SlurY%3D
    • Hirsh V. Afatinib (BIBW 2992) development in non-small-cell lung cancer. Future Oncol. 2011;7(7):817-25.
    • (2011) Future Oncol , vol.7 , Issue.7 , pp. 817-825
    • Hirsh, V.1
  • 5
    • 84879884454 scopus 로고    scopus 로고
    • Clinical perspective of afatinib in non-small cell lung cancer
    • 23664448 10.1016/j.lungcan.2013.02.021
    • Chen X, Zhu Q, Zhu L, et al. Clinical perspective of afatinib in non-small cell lung cancer. Lung Cancer. 2013;81(2):155-61.
    • (2013) Lung Cancer , vol.81 , Issue.2 , pp. 155-161
    • Chen, X.1    Zhu, Q.2    Zhu, L.3
  • 6
    • 78650945778 scopus 로고    scopus 로고
    • Afatinib (BIBW-2992): A novel dual EGFR/HER2neu inhibitor with promising activity in non-small-cell lung cancer
    • 10.2217/thy.10.86 1:CAS:528:DC%2BC3cXhs1Sju7fO
    • Bordoni RE. Afatinib (BIBW-2992): a novel dual EGFR/HER2neu inhibitor with promising activity in non-small-cell lung cancer. Therapy. 2011;8(1):15-22.
    • (2011) Therapy , vol.8 , Issue.1 , pp. 15-22
    • Bordoni, R.E.1
  • 7
    • 84858002759 scopus 로고    scopus 로고
    • Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu
    • 22325357 10.1016/j.lungcan.2012.01.008
    • De Grève J, Teugels E, Geers C, et al. Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu. Lung Cancer. 2012;76(1):123-7.
    • (2012) Lung Cancer , vol.76 , Issue.1 , pp. 123-127
    • De Grève, J.1    Teugels, E.2    Geers, C.3
  • 8
    • 84869206583 scopus 로고    scopus 로고
    • Potential of afatinib in the treatment of patients with HER2-positive breast cancer
    • 1:CAS:528:DC%2BC38XhsVCmtbzL
    • Geuna E, Montemurro F, Aglietta M, et al. Potential of afatinib in the treatment of patients with HER2-positive breast cancer. Breast Can Target Ther. 2012;4:131-7.
    • (2012) Breast Can Target Ther , vol.4 , pp. 131-137
    • Geuna, E.1    Montemurro, F.2    Aglietta, M.3
  • 9
    • 80051966802 scopus 로고    scopus 로고
    • Management of recurrent head neck cancer: Recent progress and future directions
    • 21861540 10.2165/11592540-000000000-00000 1:CAS:528:DC%2BC3MXhsVKhu7zE
    • Brockstein BE. Management of recurrent head neck cancer: recent progress and future directions. Drugs. 2011;71:1551-9.
    • (2011) Drugs , vol.71 , pp. 1551-1559
    • Brockstein, B.E.1
  • 11
    • 84884614710 scopus 로고    scopus 로고
    • US Food and Drug Administration Accessed 25 July 2013
    • US Food and Drug Administration. Afatinib. 2013. http://google2.fda.gov/ search?q=cache:MSeHvczXMGkJ:www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ ucm360574.htm+afatinib&client=FDAgov&lr=&proxystylesheet= FDAgov&output=xml-no-dtd&ie=UTF-8&site=FDAgov&access=p&oe= ISO-8859-1. Accessed 25 July 2013.
    • (2013) Afatinib
  • 12
    • 84884613850 scopus 로고    scopus 로고
    • Boehringer Ingelheim Pharmaceuticals Inc. Accessed 25 July 2013
    • Boehringer Ingelheim Pharmaceuticals Inc. Gilotrif™ (afatinib) tablets, for oral use: US prescribing information. 2013. http://www.accessdata. fda.gov/drugsatfda-docs/label/2013/201292s000lbl.pdf. Accessed 25 July 2013.
    • (2013) Gilotrif™ (Afatinib) Tablets, for Oral Use: US Prescribing Information
  • 13
    • 85081799708 scopus 로고    scopus 로고
    • European Medicines Agency Accessed 29 July 2013
    • European Medicines Agency. Giotrif (afatinib). 2013. http://www.ema. europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002280/smops/ Positive/human-smop-000570.jsp&mid=WC0b01ac058001d127&source= homeMedSearch&category=human. Accessed 29 July 2013.
    • (2013) Giotrif (Afatinib)
  • 15
    • 84867621201 scopus 로고    scopus 로고
    • Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker
    • 22888144 10.1124/jpet.112.197756 1:CAS:528:DC%2BC38XhsFKktbzE
    • Solca F, Dahl G, Zoephel A, et al. Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. J Pharmacol Exp Ther. 2012;343(2):342-50.
    • (2012) J Pharmacol Exp Ther , vol.343 , Issue.2 , pp. 342-350
    • Solca, F.1    Dahl, G.2    Zoephel, A.3
  • 16
    • 49149118719 scopus 로고    scopus 로고
    • BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
    • 18408761 10.1038/onc.2008.109 1:CAS:528:DC%2BD1cXptlKnsbk%3D
    • Li D, Ambrogio L, Shimamura T, et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene. 2008;27(34):4702-11.
    • (2008) Oncogene , vol.27 , Issue.34 , pp. 4702-4711
    • Li, D.1    Ambrogio, L.2    Shimamura, T.3
  • 17
    • 84862791294 scopus 로고    scopus 로고
    • Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: The effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab
    • 22436374 10.1186/1741-7015-10-28 1:CAS:528:DC%2BC38Xos12mtbs%3D
    • Chen G, Kronenberger P, Teugels E, et al. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab. BMC Med. 2012;10:28.
    • (2012) BMC Med , vol.10 , pp. 28
    • Chen, G.1    Kronenberger, P.2    Teugels, E.3
  • 18
    • 84877660788 scopus 로고    scopus 로고
    • Afatinib prolongs survival compared with gefitinib in an epidermal growth factor receptor-driven lung cancer model
    • 23443806 10.1158/1535-7163.MCT-12-0885 1:CAS:528:DC%2BC3sXntlSisro%3D
    • Ninomiya T, Takigawa N, Ichihara E, et al. Afatinib prolongs survival compared with gefitinib in an epidermal growth factor receptor-driven lung cancer model. Mol Cancer Ther. 2013;12(5):589-97.
    • (2013) Mol Cancer Ther , vol.12 , Issue.5 , pp. 589-597
    • Ninomiya, T.1    Takigawa, N.2    Ichihara, E.3
  • 19
    • 84977500630 scopus 로고    scopus 로고
    • Phase II, open-label trial to assess the effect of continuous oral afatinib (BIBW 2992) at a daily dose of 50 mg on QTc, pharmacokinetics, and efficacy in relapsed or refractory solid tumors including brain metastases and glioblastoma that is not amenable to other therapy
    • [abstract no. 2613]
    • Kristeleit H, Puglisi M, Middleton GW, et al. Phase II, open-label trial to assess the effect of continuous oral afatinib (BIBW 2992) at a daily dose of 50 mg on QTc, pharmacokinetics, and efficacy in relapsed or refractory solid tumors including brain metastases and glioblastoma that is not amenable to other therapy [abstract no. 2613]. J Clin Oncol. 2011;29(15 Suppl 1).
    • (2011) J Clin Oncol. , vol.29 , Issue.15 SUPPL. 1
    • Kristeleit, H.1    Puglisi, M.2    Middleton, G.W.3
  • 20
    • 84859793822 scopus 로고    scopus 로고
    • Afatinib pharmacokinetics and metabolism after oral administration to healthy male volunteers
    • 22200729 10.1007/s00280-011-1803-9 1:CAS:528:DC%2BC38XkvVCrsL4%3D
    • Stopfer P, Marzin K, Narjes H, et al. Afatinib pharmacokinetics and metabolism after oral administration to healthy male volunteers. Cancer Chemother Pharmacol. 2012;69(4):1051-61.
    • (2012) Cancer Chemother Pharmacol , vol.69 , Issue.4 , pp. 1051-1061
    • Stopfer, P.1    Marzin, K.2    Narjes, H.3
  • 21
    • 84884736973 scopus 로고    scopus 로고
    • Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations
    • 10.1200/JCO.2012.44.2806
    • Sequist LV, Yang JC, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013. doi: 10.1200/JCO.2012.44.2806.
    • (2013) J Clin Oncol
    • Sequist, L.V.1    Yang, J.C.2    Yamamoto, N.3
  • 22
    • 84884659258 scopus 로고    scopus 로고
    • LUX-Lung 6: A randomized, open-label, phase III study of afatinib (A) versus gemcitabine/cisplatin (GC) as first-line treatment for Asian patients (pts) with EGFR mutation-positive (EGFR M+) advanced adenocarcinoma of the lung
    • [abstract no. 8016]
    • Wu YL, Zhou C, Hu CP, et al. LUX-Lung 6: a randomized, open-label, phase III study of afatinib (A) versus gemcitabine/cisplatin (GC) as first-line treatment for Asian patients (pts) with EGFR mutation-positive (EGFR M+) advanced adenocarcinoma of the lung [abstract no. 8016]. J Clin Oncol. 2013;31(15 Suppl).
    • (2013) J Clin Oncol. , vol.31 , Issue.15 SUPPL.
    • Wu, Y.L.1    Zhou, C.2    Hu, C.P.3
  • 23
    • 84884658724 scopus 로고    scopus 로고
    • LUX-Lung 6: Patient-reported outcomes (PROs) from a randomized open-label, phase III study in first-line advanced NSCLC patients (pts) harboring epidermal growth factor receptor (EGFR) mutations
    • [abstract no. 8061]
    • Geater SL, Zhou C, Hu CP, et al. LUX-Lung 6: patient-reported outcomes (PROs) from a randomized open-label, phase III study in first-line advanced NSCLC patients (pts) harboring epidermal growth factor receptor (EGFR) mutations [abstract no. 8061]. J Clin Oncol. 2013;31(15 Suppl.).
    • (2013) J Clin Oncol. , vol.31 , Issue.15 SUPPL.
    • Geater, S.L.1    Zhou, C.2    Hu, C.P.3
  • 24
    • 84884605223 scopus 로고    scopus 로고
    • Symptom control and quality of life in LUX-Lung 3: A phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations
    • 10.1200/JCO.2012.46.1764
    • Yang JC, Hirsh V, Schuler M, et al. Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013. doi: 10.1200/JCO.2012.46.1764.
    • (2013) J Clin Oncol
    • Yang, J.C.1    Hirsh, V.2    Schuler, M.3
  • 25
    • 84862819699 scopus 로고    scopus 로고
    • Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): A phase 2 trial
    • 22452895 10.1016/S1470-2045(12)70086-4 1:CAS:528:DC%2BC38Xmslyhsbk%3D
    • Yang JC-H, Shih J-Y, Su W-C, et al. Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. Lancet Oncol. 2012;13(5):539-48.
    • (2012) Lancet Oncol , vol.13 , Issue.5 , pp. 539-548
    • Yang, J.-H.1    Shih, J.-Y.2    Su, W.-C.3
  • 26
    • 84862785051 scopus 로고    scopus 로고
    • Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): A phase 2b/3 randomised trial
    • 22452896 10.1016/S1470-2045(12)70087-6 1:CAS:528:DC%2BC38Xmslyhsbg%3D
    • Miller VA, Hirsh V, Cadranel J, et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol. 2012;13(5):528-38.
    • (2012) Lancet Oncol , vol.13 , Issue.5 , pp. 528-538
    • Miller, V.A.1    Hirsh, V.2    Cadranel, J.3
  • 27
    • 84873814691 scopus 로고    scopus 로고
    • Symptom and quality of life benefit of afatinib in advanced non-small-cell lung cancer patients previously treated with erlotinib or gefitinib: Results of a randomized phase IIb/III trial (LUX-Lung 1)
    • 23328549 10.1097/JTO.0b013e3182773fce 1:CAS:528:DC%2BC3sXht1KmsLs%3D
    • Hirsh V, Cadranel J, Cong XJ, et al. Symptom and quality of life benefit of afatinib in advanced non-small-cell lung cancer patients previously treated with erlotinib or gefitinib: results of a randomized phase IIb/III trial (LUX-Lung 1). J Thorac Oncol. 2013;8(2):229-37.
    • (2013) J Thorac Oncol , vol.8 , Issue.2 , pp. 229-237
    • Hirsh, V.1    Cadranel, J.2    Cong, X.J.3
  • 28
    • 84867078536 scopus 로고    scopus 로고
    • Interim analysis of afatinib monotherapy in patients with metastatic NSCLC progressing after chemotherapy and erlotinib/gefitinib (E/G) in a trial of afatinib plus paclitaxel versus investigator's choice chemotherapy following progression on afatinib monotherapy
    • [abstract no. 7557]
    • Schuler MH, Planchard D, James CHY, et al. Interim analysis of afatinib monotherapy in patients with metastatic NSCLC progressing after chemotherapy and erlotinib/gefitinib (E/G) in a trial of afatinib plus paclitaxel versus investigator's choice chemotherapy following progression on afatinib monotherapy [abstract no. 7557]. J Clin Oncol. 2012;30(15 Suppl).
    • (2012) J Clin Oncol. , vol.30 , Issue.15 SUPPL.
    • Schuler, M.H.1    Planchard, D.2    James, C.H.Y.3
  • 29
    • 84884659720 scopus 로고    scopus 로고
    • Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined non-small cell lung cancer (NSCLC) patients
    • [abstract no. 8063]
    • De Greve J, Moran T, Graas MP, et al. Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined non-small cell lung cancer (NSCLC) patients [abstract no. 8063]. J Clin Oncol. 2013;31(15 Suppl).
    • (2013) J Clin Oncol. , vol.31 , Issue.15 SUPPL.
    • De Greve, J.1    Moran, T.2    Graas, M.P.3
  • 30
    • 84859795661 scopus 로고    scopus 로고
    • Phase i study of continuous afatinib (BIBW 2992) in patients with advanced non-small cell lung cancer after prior chemotherapy/erlotinib/gefitinib (LUX-Lung 4)
    • 22071596 10.1007/s00280-011-1738-1 1:CAS:528:DC%2BC38XkvVCku7c%3D
    • Murakami H, Tamura T, Takahashi T, et al. Phase I study of continuous afatinib (BIBW 2992) in patients with advanced non-small cell lung cancer after prior chemotherapy/erlotinib/gefitinib (LUX-Lung 4). Cancer Chemother Pharmacol. 2012;69(4):891-9.
    • (2012) Cancer Chemother Pharmacol , vol.69 , Issue.4 , pp. 891-899
    • Murakami, H.1    Tamura, T.2    Takahashi, T.3
  • 31
    • 84884618137 scopus 로고    scopus 로고
    • LUX-Lung 4: A phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both
    • 10.1200/JCO.2012.45.0981 23816963
    • Katakami N, Atagi S, Goto K, et al. LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both. J Clin Oncol. 2013. doi: 10.1200/JCO.2012.45.0981.
    • (2013) J Clin Oncol
    • Katakami, N.1    Atagi, S.2    Goto, K.3
  • 32
    • 84873677937 scopus 로고    scopus 로고
    • Activity of afatinib/cetuximab in patients (pts) with EGFR mutant non-small cell lung cancer (NSCLC) and acquired resistance (AR) to EGFR inhibitors
    • [abstract no. 12270] ix401
    • Janjigian YY, Smit EF, Horn L, et al. Activity of afatinib/cetuximab in patients (pts) with EGFR mutant non-small cell lung cancer (NSCLC) and acquired resistance (AR) to EGFR inhibitors [abstract no. 12270]. Ann Oncol. 2012;23 Suppl 9:ix401.
    • (2012) Ann Oncol , vol.23 , Issue.SUPPL. 9
    • Janjigian, Y.Y.1    Smit, E.F.2    Horn, L.3
  • 33
    • 84884629596 scopus 로고    scopus 로고
    • Boehringer Ingelheim Inc. [ClinicalTrials.gov identifier NCT01090011] US National Institutes of Health, ClinicalTrials.gov Accessed 12 Aug 2013
    • Boehringer Ingelheim Inc. Trial of BIBW 2992 (afatinib) + cetuximab in non-small cell lung cancer [ClinicalTrials.gov identifier NCT01090011] US National Institutes of Health, ClinicalTrials.gov. 2013. http://www. clinicaltrials.gov/ct2/show/NCT01090011?term=afatinib+cetuximab&rank=2. Accessed 12 Aug 2013.
    • (2013) Trial of BIBW 2992 (Afatinib) + Cetuximab in Non-small Cell Lung Cancer
  • 35
    • 85081799140 scopus 로고    scopus 로고
    • Phase II trial of afatinib as a third-line treatment for Korean patients with wild-type epidermal growth factor receptor stage IIIb/IV lung adenocarcinoma [poster]
    • 28 Sep-2 Oct 2012; Vienna
    • Ahn J-H, Kim S-W, Cho B-C, et al. Phase II trial of afatinib as a third-line treatment for Korean patients with wild-type epidermal growth factor receptor stage IIIb/IV lung adenocarcinoma [poster]. 37th Congress of the European Society for Medical Oncology; 28 Sep-2 Oct 2012; Vienna.
    • 37th Congress of the European Society for Medical Oncology
    • Ahn, J.-H.1    Kim, S.-W.2    Cho, B.-C.3
  • 36
    • 85081795717 scopus 로고    scopus 로고
    • LUX-Lung 8: A randomized, open-label, phase III trial of afatinib vs. Erlotinib in patients with advanced squamous cell carcinoma of the lung as second-line therapy following first-line platinum-based chemotherapy
    • [abstract no. 509TiP] 28 Sep-2 Oct 2012; Vienna
    • Goss G, Lu S, Felip E, et al. LUX-Lung 8: a randomized, open-label, phase III trial of afatinib vs. erlotinib in patients with advanced squamous cell carcinoma of the lung as second-line therapy following first-line platinum-based chemotherapy [abstract no. 509TiP]. 37th Congress of the European Society for Medical Oncology; 28 Sep-2 Oct 2012; Vienna.
    • 37th Congress of the European Society for Medical Oncology
    • Goss, G.1    Lu, S.2    Felip, E.3
  • 40
    • 85081795229 scopus 로고    scopus 로고
    • National Cancer Center Korea [ClinicalTrials.gov identifier NCT01156545] US National Institutes of Health, ClinicalTrials.gov Accessed 25 July 2013
    • National Cancer Center Korea. BIBW 2992 plus simvastatin vs. BIBW 2992 in previously treated patients with advanced non-adenocarcinomatous NSCLC [ClinicalTrials.gov identifier NCT01156545] US National Institutes of Health, ClinicalTrials.gov. 2012. http://www.clinicaltrials.gov/ct2/show/NCT01156545? term=NCT01156545&rank=1. Accessed 25 July 2013.
    • (2012) BIBW 2992 Plus Simvastatin Vs. BIBW 2992 in Previously Treated Patients with Advanced Non-adenocarcinomatous NSCLC
  • 41
    • 85081800144 scopus 로고    scopus 로고
    • Instituto Nacional de Cancerologia de Mexico [ClinicalTrials.gov identifier NCT01542437] US National Institutes of Health, ClinicalTrials.gov Accessed 12 Aug 2013
    • Instituto Nacional de Cancerologia de Mexico. Treatment with BIBW 2992, irreversible inhibitor of EGFR and HER-2 in non small cell lung cancer (NSCLC) [ClinicalTrials.gov identifier NCT01542437] US National Institutes of Health, ClinicalTrials.gov. 2013. http://www.clinicaltrials.gov/ct2/show/NCT01542437? term=afatinib&rank=51. Accessed 12 Aug 2013.
    • (2013) Treatment with BIBW 2992, Irreversible Inhibitor of EGFR and HER-2 in Non Small Cell Lung Cancer (NSCLC)
  • 42
    • 85081792503 scopus 로고    scopus 로고
    • Massachusetts General Hospital [ClinicalTrials.gov identifier NCT01553942] US National Institutes of Health, ClinicalTrials.gov 2013 Accessed 12 Aug 2013
    • Massachusetts General Hospital. Afatinib with CT and RT for EGFR-mutant NSCLC [ClinicalTrials.gov identifier NCT01553942] US National Institutes of Health, ClinicalTrials.gov. 2013. http://www.clinicaltrials.gov/ct2/show/ NCT01553942?term=afatinib&rank=44. Accessed 12 Aug 2013.
    • Afatinib with CT and RT for EGFR-mutant NSCLC
  • 43
    • 85081793785 scopus 로고    scopus 로고
    • Massachusetts General Hospital [ClinicalTrials.gov identifier NCT01746251] US National Institutes of Health, ClinicalTrials.gov Accessed 12 Aug 2013
    • Massachusetts General Hospital. Adjuvant afatinib in stage I-III NSCLC with EGFR mutation [ClinicalTrials.gov identifier NCT01746251] US National Institutes of Health, ClinicalTrials.gov. 2013. http://www.clinicaltrials.gov/ ct2/show/NCT01746251?term=afatinib&rank=42. Accessed 12 Aug 2013.
    • (2013) Adjuvant Afatinib in Stage I-III NSCLC with EGFR Mutation
  • 44
    • 85081801460 scopus 로고    scopus 로고
    • Samsung Medical Center [ClinicalTrials.gov identifier NCT01861223] US National Institutes of Health, ClinicalTrials.gov Accessed 12 Aug 2013
    • Samsung Medical Center. Afatinib plus nimotuzumb for NSCLC [ClinicalTrials.gov identifier NCT01861223] US National Institutes of Health, ClinicalTrials.gov. 2013. http://www.clinicaltrials.gov/ct2/show/NCT01861223? term=afatinib&rank=64. Accessed 12 Aug 2013.
    • (2013) Afatinib Plus Nimotuzumb for NSCLC
  • 48
    • 85081795790 scopus 로고    scopus 로고
    • University College London [ClinicalTrials.gov identifier NCT01415011] US National Institutes of Health, ClinicalTrials.gov Accessed 12 Aug 2013
    • University College London. Efficacy and safety study of BIBW 2992 to treat lung cancer patients (TIMELY) [ClinicalTrials.gov identifier NCT01415011] US National Institutes of Health, ClinicalTrials.gov. 2013. http://www. clinicaltrials.gov/ct2/show/NCT01415011?term=afatinib&rank=72. Accessed 12 Aug 2013.
    • (2013) Efficacy and Safety Study of BIBW 2992 to Treat Lung Cancer Patients (TIMELY)
  • 49
    • 85081797943 scopus 로고    scopus 로고
    • Boehringer Ingelheim Pharmaceuticals [ClinicalTrials.gov identifier NCT01649284] US National Institutes of Health, ClinicalTrials.gov Accessed 25 July 2013
    • Boehringer Ingelheim Pharmaceuticals. Afatinib expanded access program [ClinicalTrials.gov identifier NCT01649284] US National Institutes of Health, ClinicalTrials.gov. 2013. http://www.clinicaltrials.gov/ct2/show/NCT01649284? term=NCT01649284&rank=1. Accessed 25 July 2013.
    • (2013) Afatinib Expanded Access Program
  • 50
    • 84868191989 scopus 로고    scopus 로고
    • A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer
    • 22763464 10.1007/s10549-012-2126-1 1:CAS:528:DC%2BC38XhtFCrsrzO
    • Schuler M, Awada A, Harter P, et al. A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer. Breast Cancer Res Treat. 2012;134(3):1149-59.
    • (2012) Breast Cancer Res Treat , vol.134 , Issue.3 , pp. 1149-1159
    • Schuler, M.1    Awada, A.2    Harter, P.3
  • 51
    • 84863715765 scopus 로고    scopus 로고
    • A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab
    • 22418700 10.1007/s10549-012-2003-y 1:CAS:528:DC%2BC38XpvFeqsLg%3D
    • Lin NU, Winer EP, Wheatley D, et al. A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab. Breast Cancer Res Treat. 2012;133(3):1057-65.
    • (2012) Breast Cancer Res Treat , vol.133 , Issue.3 , pp. 1057-1065
    • Lin, N.U.1    Winer, E.P.2    Wheatley, D.3
  • 52
    • 84856063645 scopus 로고    scopus 로고
    • Addition of BIBW 2992, an irreversible inhibitor of EGFR/HER1 and HER2, to letrozole in estrogen receptor (ER)-positive metastatic breast cancer (mBC) progressing on letrozole monotherapy
    • [abstract no. 1072] plus poster presented at the 46th Annual Meeting of the American Society of Clinical Oncology; 4-8 Jun 2010; Chicago (IL)
    • Gunzer K, De Mont-Serrat H, Uttenreuther-Fischer MM, et al. Addition of BIBW 2992, an irreversible inhibitor of EGFR/HER1 and HER2, to letrozole in estrogen receptor (ER)-positive metastatic breast cancer (mBC) progressing on letrozole monotherapy [abstract no. 1072]. J Clin Oncol. 2010;28(15 Suppl 1): plus poster presented at the 46th Annual Meeting of the American Society of Clinical Oncology; 4-8 Jun 2010; Chicago (IL).
    • (2010) J Clin Oncol. , vol.28 , Issue.15 SUPPL. 1
    • Gunzer, K.1    De Mont-Serrat, H.2    Uttenreuther-Fischer, M.M.3
  • 53
    • 84870635223 scopus 로고    scopus 로고
    • A neoadjuvant, randomized, open-label phase II trial of afatinib (A) versus trastuzumab (T) versus lapatinib (L) in patients (pts) with locally advanced HER2-positive breast cancer (BC)
    • [abstract no. 606]
    • Rimawi MF, Aleixo SB, Rozas AA, et al. A neoadjuvant, randomized, open-label phase II trial of afatinib (A) versus trastuzumab (T) versus lapatinib (L) in patients (pts) with locally advanced HER2-positive breast cancer (BC) [abstract no. 606]. J Clin Oncol. 2012;30(15 Suppl 1).
    • (2012) J Clin Oncol. , vol.30 , Issue.15 SUPPL. 1
    • Rimawi, M.F.1    Aleixo, S.B.2    Rozas, A.A.3
  • 54
    • 85081797497 scopus 로고    scopus 로고
    • LUX-Breast 1: Randomized, phase III trial of afatinib (BIBW 2992) and vinorelbine vs. Trastuzumab and vinorelbine in patients with HER2-overexpressing metastatic breast cancer (MBC) failing one prior trastuzumab treatment
    • [abstract no. OT1-1-16]
    • Xu B, Im SA, Huang CS, et al. LUX-Breast 1: randomized, phase III trial of afatinib (BIBW 2992) and vinorelbine vs. trastuzumab and vinorelbine in patients with HER2-overexpressing metastatic breast cancer (MBC) failing one prior trastuzumab treatment [abstract no. OT1-1-16]. Cancer Res. 2012;72(24 Suppl 3).
    • (2012) Cancer Res. , vol.72 , Issue.24 SUPPL. 3
    • Xu, B.1    Im, S.A.2    Huang, C.S.3
  • 55
    • 84884621955 scopus 로고    scopus 로고
    • LUX-Breast 2: Phase II, Open-label Study of Oral Afatinib in HER2-overexpressing Metastatic Breast Cancer (MBC) Patients (PTS) Who Progressed on Prior Trastuzumab And/or Lapatinib
    • [abstract no. OT1-1-17]
    • Hickish T, Mehta A, Jain M, et al. LUX-Breast 2: phase II, open-label study of oral afatinib in HER2-overexpressing metastatic breast cancer (MBC) patients (PTS) who progressed on prior trastuzumab and/or lapatinib [abstract no. OT1-1-17]. Cancer Res. 2012;72(24 Suppl 3).
    • (2012) Cancer Res. , vol.72 , Issue.24 SUPPL. 3
    • Hickish, T.1    Mehta, A.2    Jain, M.3
  • 56
    • 84884599318 scopus 로고    scopus 로고
    • LUX-Breast 3: Randomized phase II trial of afatinib (BIBW 2992) alone or with vinorelbine versus investigator's choice of treatment in patients (PTS) with HER2-positive breast cancer (BC) with progressive brain metastases after trastuzumab and/or lapatinib-based therapy
    • [abstract no. OT1-1-15]
    • Joensuu H, Ould-Kaci M. LUX-Breast 3: randomized phase II trial of afatinib (BIBW 2992) alone or with vinorelbine versus investigator's choice of treatment in patients (PTS) with HER2-positive breast cancer (BC) with progressive brain metastases after trastuzumab and/or lapatinib-based therapy [abstract no. OT1-1-15]. Cancer Res. 2012;72(24 Suppl 3).
    • (2012) Cancer Res. , vol.72 , Issue.24 SUPPL. 3
    • Joensuu, H.1    Ould-Kaci, M.2
  • 57
    • 84884639882 scopus 로고    scopus 로고
    • Open-label, phase II trial of afatinib, with or without vinorelbine (V), for the treatment of HER2-overexpressing inflammatory breast cancer (IBC)
    • [abstract no. TPS650]
    • Swanton C, Cromer J. Open-label, phase II trial of afatinib, with or without vinorelbine (V), for the treatment of HER2-overexpressing inflammatory breast cancer (IBC) [abstract no. TPS650]. J Clin Oncol. 2012;30(15 Suppl 1).
    • (2012) J Clin Oncol. , vol.30 , Issue.15 SUPPL. 1
    • Swanton, C.1    Cromer, J.2
  • 58
    • 85081792932 scopus 로고    scopus 로고
    • Dual blockade with afatinib and trastuzumab as neooadjuvant treatment for patients with locally advanced or operable breast cancer receiving taxane-anthracycline containing chemotherapy
    • (DAFNE)-GBG70 [abstract no. OT1-1-13]
    • Hanusch C, Schneeweiss A, Untch M, et al. Dual blockade with afatinib and trastuzumab as neooadjuvant treatment for patients with locally advanced or operable breast cancer receiving taxane-anthracycline containing chemotherapy (DAFNE)-GBG70 [abstract no. OT1-1-13]. Cancer Res. 2012;72(24 Suppl 3).
    • (2012) Cancer Res. , vol.72 , Issue.24 SUPPL. 3
    • Hanusch, C.1    Schneeweiss, A.2    Untch, M.3
  • 60
    • 84885435197 scopus 로고    scopus 로고
    • A randomized, open-label, phase II study of afatinib (BIBW 2992) versus cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck: Final data [abstract no. PP101]
    • Cohen EEW, Fayette J, Cupissol D, et al. A randomized, open-label, phase II study of afatinib (BIBW 2992) versus cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck: final data [abstract no. PP101]. Eur Arch Otorhinolaryngol. 2012;269(4):1374.
    • (2012) Eur Arch Otorhinolaryngol , vol.269 , Issue.4 , pp. 1374
    • Cohen, E.E.W.1    Fayette, J.2    Cupissol, D.3
  • 61
    • 84896704289 scopus 로고    scopus 로고
    • LUX-Head and Neck 1: A phase III, randomized trial of afatinib versus methotrexate (MTX) in patients (pts) with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) who progressed after platinum-based therapy
    • [abstract no. TPS5598]
    • Machiels JPH, Licitra LF, Haddad RI, et al. LUX-Head and Neck 1: a phase III, randomized trial of afatinib versus methotrexate (MTX) in patients (pts) with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) who progressed after platinum-based therapy [abstract no. TPS5598]. J Clin Oncol. 2012;30(15 Suppl 1).
    • (2012) J Clin Oncol. , vol.30 , Issue.15 SUPPL. 1
    • Machiels, J.P.H.1    Licitra, L.F.2    Haddad, R.I.3
  • 62
    • 84884615858 scopus 로고    scopus 로고
    • LUX-Head and Neck 2: A randomized, double-blind, placebo-controlled, phase III study of afatinib as adjuvant therapy after chemoradiation in primarily unresected, clinically high-risk, head and neck cancer patients
    • [abstract no. TPS5599]
    • Burtness B, Bourhis J, Vermorken JB, et al. LUX-Head and Neck 2: a randomized, double-blind, placebo-controlled, phase III study of afatinib as adjuvant therapy after chemoradiation in primarily unresected, clinically high-risk, head and neck cancer patients [abstract no. TPS5599]. J Clin Oncol. 2012;30(15 Suppl 1).
    • (2012) J Clin Oncol. , vol.30 , Issue.15 SUPPL. 1
    • Burtness, B.1    Bourhis, J.2    Vermorken, J.B.3
  • 64
    • 84873521765 scopus 로고    scopus 로고
    • A phase II study of afatinib (BIBW 2992) in patients with advanced HER2-positive trastuzumab-refractory esophagogastric cancer
    • [abstract no. e15017]
    • Janjigian YY, Ilson D, Kelsen DP, et al. A phase II study of afatinib (BIBW 2992) in patients with advanced HER2-positive trastuzumab-refractory esophagogastric cancer [abstract no. e15017]. J Clin Oncol. 2012;30(15 Suppl 1).
    • (2012) J Clin Oncol. , vol.30 , Issue.15 SUPPL. 1
    • Janjigian, Y.Y.1    Ilson, D.2    Kelsen, D.P.3
  • 65
    • 80053583913 scopus 로고    scopus 로고
    • A phase II study of daily afatinib (BIBW 2992) with or without temozolomide (21/28 days) in the treatment of patients with recurrent glioblastoma
    • [abstract no. 2010]
    • Eisenstat DD, Nabors LB, Mason WP, et al. A phase II study of daily afatinib (BIBW 2992) with or without temozolomide (21/28 days) in the treatment of patients with recurrent glioblastoma [abstract no. 2010]. J Clin Oncol. 2011;29(15 Suppl 1).
    • (2011) J Clin Oncol. , vol.29 , Issue.15 SUPPL. 1
    • Eisenstat, D.D.1    Nabors, L.B.2    Mason, W.P.3
  • 66
    • 79960443101 scopus 로고    scopus 로고
    • Phase II trial of weekly alternating sequential BIBF 1120 and afatinib for advanced colorectal cancer
    • 21737652 1:CAS:528:DC%2BC3MXpsVylsro%3D
    • Bouche O, Maindrault-Goebel F, Ducreux M, et al. Phase II trial of weekly alternating sequential BIBF 1120 and afatinib for advanced colorectal cancer. Anticancer Res. 2011;31(6):2271-81.
    • (2011) Anticancer Res , vol.31 , Issue.6 , pp. 2271-2281
    • Bouche, O.1    Maindrault-Goebel, F.2    Ducreux, M.3
  • 67
    • 84870821895 scopus 로고    scopus 로고
    • A phase II trial to compare BIBF 1120 or BIBW 2992 monotherapy versus a combination of sequential administration of both medications in patients with hormone refractory prostate cancer
    • [abstract no. 203] 26-28 Feb 2009; Orlando (FL)
    • Molife R, De Bono JS, Bell S. A phase II trial to compare BIBF 1120 or BIBW 2992 monotherapy versus a combination of sequential administration of both medications in patients with hormone refractory prostate cancer [abstract no. 203]. 2009 Genitourinary Cancers Symposium; 26-28 Feb 2009; Orlando (FL).
    • 2009 Genitourinary Cancers Symposium
    • Molife, R.1    De Bono, J.S.2    Bell, S.3
  • 68
    • 85081796258 scopus 로고    scopus 로고
    • Memorial Sloan-Kettering Cancer Center [ClinicalTrials.gov identifier NCT01522768] US National Institutes of Health, ClinicalTrials.gov Accessed 29 July 2013
    • Memorial Sloan-Kettering Cancer Center. Afatinib (BIBW 2992) in patients with advanced HER2-positive trastuzumab-refractory advanced esophagogastric cancer [ClinicalTrials.gov identifier NCT01522768] US National Institutes of Health, ClinicalTrials.gov. 2013. http://www.clinicaltrials.gov/ct2/show/ NCT01522768?term=afatinib+AND+gastric&rank=2. Accessed 29 July 2013.
    • (2013) Afatinib (BIBW 2992) in Patients with Advanced HER2-positive Trastuzumab-refractory Advanced Esophagogastric Cancer
  • 69
    • 85081801129 scopus 로고    scopus 로고
    • Boehringer Ingelheim Pharmaceuticals [ClinicalTrials.gov identifier NCT00727506] US National Institutes of Health, ClinicalTrials.gov Accessed 29 July 2013
    • Boehringer Ingelheim Pharmaceuticals. BIBW 2992 (afatinib) with or without daily temozolomide in the treatment of patients with recurrent malignant glioma [ClinicalTrials.gov identifier NCT00727506] US National Institutes of Health, ClinicalTrials.gov. 2013. http://www.clinicaltrials.gov/ct2/show/ NCT00727506?term=NCT00727506&rank=1. Accessed 29 July 2013.
    • (2013) BIBW 2992 (Afatinib) with or Without Daily Temozolomide in the Treatment of Patients with Recurrent Malignant Glioma
  • 72
    • 85081794368 scopus 로고    scopus 로고
    • Hellenic Cooperative Oncology Group [ClinicalTrials.gov identifier NCT01743365] US National Institutes of Health, ClinicalTrials.gov Accessed 29 July 2013
    • Hellenic Cooperative Oncology Group. Clinical trial of chemotherapy combination cisplatin-fluorouracil-afatinib in patients with inoperable gastric cancer (A-GAPP) [ClinicalTrials.gov identifier NCT01743365] US National Institutes of Health, ClinicalTrials.gov. 2013. http://www.clinicaltrials.gov/ ct2/show/NCT01743365?term=afatinib+AND+gastric&rank=1. Accessed 29 July 2013.
    • (2013) Clinical Trial of Chemotherapy Combination Cisplatin-fluorouracil- afatinib in Patients with Inoperable Gastric Cancer (A-GAPP)
  • 73
    • 84879551355 scopus 로고    scopus 로고
    • A Phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumors
    • 23242861 10.1007/s10637-012-9904-9 1:CAS:528:DC%2BC3sXjsleisL0%3D
    • Gordon MS, Mendelson DS, Gross M, et al. A Phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumors. Invest New Drugs. 2013;31(2):409-16.
    • (2013) Invest New Drugs , vol.31 , Issue.2 , pp. 409-416
    • Gordon, M.S.1    Mendelson, D.S.2    Gross, M.3
  • 74
    • 77957585027 scopus 로고    scopus 로고
    • Phase i trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors
    • 20679611 10.1200/JCO.2009.26.7278 1:CAS:528:DC%2BC3cXht1eqsbzF
    • Yap TA, Vidal L, Adam J, et al. Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors. J Clin Oncol. 2010;28(25):3965-72.
    • (2010) J Clin Oncol , vol.28 , Issue.25 , pp. 3965-3972
    • Yap, T.A.1    Vidal, L.2    Adam, J.3
  • 75
    • 84879551143 scopus 로고    scopus 로고
    • A phase I, open-label, dose escalation study of afatinib, in a 3-week-on/1-week-off schedule in patients with advanced solid tumors
    • 23161335 10.1007/s10637-012-9890-y 1:CAS:528:DC%2BC3sXjsleisLk%3D
    • Marshall J, Hwang J, Eskens FALM, et al. A phase I, open-label, dose escalation study of afatinib, in a 3-week-on/1-week-off schedule in patients with advanced solid tumors. Invest New Drugs. 2013;31(2):399-408.
    • (2013) Invest New Drugs , vol.31 , Issue.2 , pp. 399-408
    • Marshall, J.1    Hwang, J.2    Eskens, F.3
  • 76
    • 38049038935 scopus 로고    scopus 로고
    • A phase i dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours
    • 18026190 10.1038/sj.bjc.6604108 1:CAS:528:DC%2BD1cXisF2qtg%3D%3D
    • Eskens FALM, Mom CH, Planting AST, et al. A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours. Br J Cancer. 2008;98(1):80-5.
    • (2008) Br J Cancer , vol.98 , Issue.1 , pp. 80-85
    • Eskens, F.1    Mom, C.H.2    Planting, A.S.T.3
  • 77
    • 84879092054 scopus 로고    scopus 로고
    • Phase i study of pulsatile 3-day administration of afatinib (BIBW 2992) in combination with docetaxel in advanced solid tumors
    • 23161334 10.1007/s10637-012-9880-0 1:CAS:528:DC%2BC3sXnt12lsr4%3D
    • Awada AH, Dumez H, Hendlisz A, et al. Phase I study of pulsatile 3-day administration of afatinib (BIBW 2992) in combination with docetaxel in advanced solid tumors. Invest New Drugs. 2013;31(3):734-41.
    • (2013) Invest New Drugs , vol.31 , Issue.3 , pp. 734-741
    • Awada, A.H.1    Dumez, H.2    Hendlisz, A.3
  • 78
    • 84874096332 scopus 로고    scopus 로고
    • Phase i dose-escalation study of afatinib, an ErbB family blocker, plus docetaxel in patients with advanced cancer
    • 23414476 10.2217/fon.12.195 1:CAS:528:DC%2BC3sXis1Chs78%3D
    • Marshall J, Shapiro GI, Uttenreuther-Fischer M, et al. Phase I dose-escalation study of afatinib, an ErbB family blocker, plus docetaxel in patients with advanced cancer. Future Oncol. 2013;9(2):271-81.
    • (2013) Future Oncol , vol.9 , Issue.2 , pp. 271-281
    • Marshall, J.1    Shapiro, G.I.2    Uttenreuther-Fischer, M.3
  • 79
    • 84877148074 scopus 로고    scopus 로고
    • A phase Ib, open-label study to assess the safety of continuous oral treatment with afatinib in combination with two chemotherapy regimens: Cisplatin plus paclitaxel and cisplatin plus 5-fluorouracil, in patients with advanced solid tumors
    • 23293114 10.1093/annonc/mds633 1:STN:280:DC%2BC3s3ntFCgsg%3D%3D
    • Vermorken JB, Rottey S, Ehrnrooth E, et al. A phase Ib, open-label study to assess the safety of continuous oral treatment with afatinib in combination with two chemotherapy regimens: cisplatin plus paclitaxel and cisplatin plus 5-fluorouracil, in patients with advanced solid tumors. Ann Oncol. 2013;24(5):1392-400.
    • (2013) Ann Oncol , vol.24 , Issue.5 , pp. 1392-1400
    • Vermorken, J.B.1    Rottey, S.2    Ehrnrooth, E.3
  • 80
    • 85081796641 scopus 로고    scopus 로고
    • Phase i safety and tolerability of once daily oral afatinib (A) in combination with gemcitabine (G) in patients with advanced solid tumors
    • [abstract no. e13009]
    • Zanetta S, Bennouna J, Isambert N, et al. Phase I safety and tolerability of once daily oral afatinib (A) in combination with gemcitabine (G) in patients with advanced solid tumors [abstract no. e13009]. J Clin Oncol. 2012;30(15 Suppl 1).
    • (2012) J Clin Oncol. , vol.30 , Issue.15 SUPPL. 1
    • Zanetta, S.1    Bennouna, J.2    Isambert, N.3
  • 81
    • 84870632446 scopus 로고    scopus 로고
    • Phase i trial to assess the safety and pharmacokinetics of afatinib and weekly vinorelbine in patients with advanced solid tumors
    • [abstract no. 3104]
    • Hollebecque A, Bahleda R, Berge Y, et al. Phase I trial to assess the safety and pharmacokinetics of afatinib and weekly vinorelbine in patients with advanced solid tumors [abstract no. 3104]. J Clin Oncol. 2012;30(15 Suppl 1).
    • (2012) J Clin Oncol. , vol.30 , Issue.15 SUPPL. 1
    • Hollebecque, A.1    Bahleda, R.2    Berge, Y.3
  • 82
    • 84884656251 scopus 로고    scopus 로고
    • A phase I, dose-escalation trial of continuous and pulsed-dose afatinib (A) combined with pemetrexed (P) in patients (pts) with advanced solid tumors: Final analysis
    • [abstract no. 2523]
    • Chu QS, Sangha RS, Hotte SJ, et al. A phase I, dose-escalation trial of continuous and pulsed-dose afatinib (A) combined with pemetrexed (P) in patients (pts) with advanced solid tumors: final analysis [abstract no. 2523]. J Clin Oncol. 2013;31(15 Suppl 1).
    • (2013) J Clin Oncol. , vol.31 , Issue.15 SUPPL. 1
    • Chu, Q.S.1    Sangha, R.S.2    Hotte, S.J.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.